Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 17/20 | 0.66 |
| ▸ | MTNR1B | P49286 | 17/20 | 0.66 |
| ▸ | NQO2 | P16083 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18222545 | 0.84 | MTNR1A (0.62) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 | |
| SCHEMBL18222551 | 0.82 | MTNR1A (0.68) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 | |
| SCHEMBL18239715 | 0.82 | MTNR1A (0.62) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 | |
| SCHEMBL18239691 | 0.82 | MTNR1A (0.74) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 | |
| SCHEMBL18239792 | 0.80 | MTNR1A (0.68) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 | |
| SCHEMBL8946916 | 0.80 | MTNR1A (1.00) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 | |
| SCHEMBL31543713 | 0.80 | MTNR1A (1.00) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 | |
| SCHEMBL18222496 | 0.75 | MTNR1A (0.50) | MTNR1AMTNR1BALDH1A1POLB | |
| SCHEMBL18222513 | 0.75 | MTNR1A (0.50) | MTNR1AMTNR1BALDH1A1POLB | |
| SCHEMBL31543625 | 0.74 | SPR (0.72) | MTNR1AMTNR1BNQO2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637451-B2 | Indole compound | ASTELLAS PHARMA INC. (JP) | 2017-05-02 | — | — | US | disclosed |
| US-20160332966-A1 | INDOLE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332966-A1 | INDOLE COMPOUND | MTNR1A, MTNR1B, IDO2 | MTNR1A 1/4885MTNR1B 2/4885NQO2 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.